Emergent BioSolutions (EBS) insider has shares withheld to cover taxes

Rhea-AI Filing Summary

Emergent BioSolutions reported an insider transaction by an officer serving as senior vice president of R&D and chief medical officer. On December 14, 2025, 3,543 shares of common stock were withheld at a price of $11.41 per share to pay taxes due when restricted stock units vested and settled.

After this tax withholding, the officer directly beneficially owns 88,439 shares of Emergent BioSolutions common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lowry Simon C

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, R&D, CMO

3. Date of Earliest Transaction (Month/Day/Year)
12/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/14/2025	12/15/2025	F		3,543(1)	D	$11.41	88,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

Remarks:

	/s/ Jessica Perl, Attorney-in-fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Emergent BioSolutions (EBS) report in this Form 4?

The filing shows that 3,543 shares of Emergent BioSolutions common stock were withheld on December 14, 2025 at $11.41 per share to pay taxes tied to the vesting and settlement of restricted stock units.

Who is the reporting person in this Emergent BioSolutions (EBS) insider filing and what is their role?

The reporting person is an officer of Emergent BioSolutions serving as senior vice president of R&D and chief medical officer, as indicated in the relationship section.

How many Emergent BioSolutions (EBS) shares does the insider own after the reported transaction?

Following the reported tax withholding transaction, the officer beneficially owns 88,439 shares of Emergent BioSolutions common stock in direct ownership.

What was the price used for the Emergent BioSolutions (EBS) shares withheld for taxes?

The 3,543 shares of Emergent BioSolutions common stock withheld to cover taxes were valued at $11.41 per share on the transaction date.

Why were shares withheld in this Emergent BioSolutions (EBS) Form 4 transaction?

The explanation of responses states that the reported 3,543 shares represent common stock withheld to pay taxes associated with the vesting and settlement of restricted stock units.

Is this Emergent BioSolutions (EBS) insider transaction classified as an acquisition or a disposition of shares?

In the Form 4 table, the transaction is marked as a disposition (D) of 3,543 shares of common stock, reflecting the shares withheld for tax purposes.